[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL152180A0 - Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents - Google Patents

Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Info

Publication number
IL152180A0
IL152180A0 IL15218001A IL15218001A IL152180A0 IL 152180 A0 IL152180 A0 IL 152180A0 IL 15218001 A IL15218001 A IL 15218001A IL 15218001 A IL15218001 A IL 15218001A IL 152180 A0 IL152180 A0 IL 152180A0
Authority
IL
Israel
Prior art keywords
apoptosis
administration
composition
treating cancer
chemotherapeutic agents
Prior art date
Application number
IL15218001A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL152180A0 publication Critical patent/IL152180A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
IL15218001A 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents IL152180A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19592000P 2000-04-10 2000-04-10
PCT/US2001/011688 WO2001076567A1 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Publications (1)

Publication Number Publication Date
IL152180A0 true IL152180A0 (en) 2003-05-29

Family

ID=22723363

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15218001A IL152180A0 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Country Status (19)

Country Link
US (1) US20020041888A1 (xx)
EP (1) EP1274404A1 (xx)
JP (1) JP2004507451A (xx)
KR (1) KR20030008368A (xx)
CN (1) CN1438882A (xx)
AU (1) AU2001253334A1 (xx)
BR (1) BR0110150A (xx)
CA (1) CA2406484A1 (xx)
CZ (1) CZ20023333A3 (xx)
EA (1) EA200201068A1 (xx)
HU (1) HUP0302296A2 (xx)
IL (1) IL152180A0 (xx)
MX (1) MXPA02009984A (xx)
NO (1) NO20024867L (xx)
PL (1) PL366035A1 (xx)
SK (1) SK14452002A3 (xx)
WO (1) WO2001076567A1 (xx)
YU (1) YU77002A (xx)
ZA (1) ZA200208167B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
KR20050026699A (ko) * 2002-04-26 2005-03-15 테바 파마슈티컬 인더스트리즈 리미티드 종양내 전달을 위한 마이크로입자 약학 조성물
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇-海藻酸钠微球血管栓塞剂及其制备
AU2005299748B2 (en) * 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
AU2006243337B2 (en) * 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
ES2609388T3 (es) 2006-03-22 2017-04-20 Syncore Biotechnology Co., Ltd Tratamiento del cáncer de mama triple negativo a receptores
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
PT2552415T (pt) 2010-03-29 2016-11-04 Abraxis Bioscience Llc Métodos de tratamento do cancro
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
WO2012094620A2 (en) 2011-01-09 2012-07-12 Anp Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins

Also Published As

Publication number Publication date
EP1274404A1 (en) 2003-01-15
JP2004507451A (ja) 2004-03-11
SK14452002A3 (sk) 2003-07-01
ZA200208167B (en) 2004-02-10
NO20024867L (no) 2002-12-06
PL366035A1 (en) 2005-01-24
EA200201068A1 (ru) 2003-12-25
CZ20023333A3 (cs) 2003-06-18
CN1438882A (zh) 2003-08-27
BR0110150A (pt) 2004-04-27
CA2406484A1 (en) 2001-10-18
YU77002A (sh) 2005-09-19
WO2001076567A1 (en) 2001-10-18
HUP0302296A2 (hu) 2003-10-28
KR20030008368A (ko) 2003-01-25
NO20024867D0 (no) 2002-10-09
AU2001253334A1 (en) 2001-10-23
MXPA02009984A (es) 2004-09-10
US20020041888A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1229934A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS
HUP0301690A3 (en) Synergistic methods and compositions for treating cancer
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
HUP0203304A3 (en) Method and composition for chemoprevention of prostate cancer
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
PL352931A1 (en) Compositions and uses of et743 for treating cancer
IL152180A0 (en) Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
EP1379242A4 (en) METHOD OF TREATING CANCERS AND APPROPRIATE COMPOSITIONS
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU2001278558A1 (en) Use of co for treating inflammation of upper airways or bronchi
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL145397A0 (en) Compositions and methods for treatment of cancer
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
HUP0300860A3 (en) Pharmaceutical compositions suitable for treatment of urinary dysfunction
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2001253836A1 (en) Method of treating cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
HUP0302430A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
IL154354A0 (en) Composition for prophylaxis and treatment of cancer
EP1423118A4 (en) METHOD AND COMPOSITION FOR CANCER TREATMENT